BENZALKONIUM CHLORIDE 0.13% and PULMONARY TOXICITY

Overview

PULMONARY TOXICITY is the #15 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 103 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to PULMONARY TOXICITY. This represents approximately 3.1% of all 3,369 adverse event reports for this drug.

Patients taking BENZALKONIUM CHLORIDE 0.13% who experience pulmonary toxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PULMONARY TOXICITY is moderately reported among BENZALKONIUM CHLORIDE 0.13% users, representing a notable but not dominant share of adverse events.

Other Side Effects of BENZALKONIUM CHLORIDE 0.13%

In addition to pulmonary toxicity, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:

• DRUG INEFFECTIVE — 124 reports
• DRUG HYPERSENSITIVITY — 116 reports
• CONDITION AGGRAVATED — 112 reports
• ARTHRALGIA — 110 reports
• THERAPY NON RESPONDER — 110 reports
• MUSCULOSKELETAL STIFFNESS — 108 reports
• PAIN IN EXTREMITY — 108 reports
• INFECTION — 107 reports
• HEPATOTOXICITY — 105 reports
• JOINT SWELLING — 105 reports

Other Drugs Associated with PULMONARY TOXICITY

The following drugs have also been linked to pulmonary toxicity in FDA adverse event reports:

Does BENZALKONIUM CHLORIDE 0.13% cause PULMONARY TOXICITY?

PULMONARY TOXICITY has been reported as an adverse event in 103 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PULMONARY TOXICITY with BENZALKONIUM CHLORIDE 0.13%?

PULMONARY TOXICITY accounts for approximately 3.1% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.

What should I do if I experience PULMONARY TOXICITY while taking BENZALKONIUM CHLORIDE 0.13%?

If you experience pulmonary toxicity while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages